Shield Diagnostics (UK) names Wallac (US) as neonatal distributor:
This article was originally published in Clinica
Shield Diagnostics (UK) has appointed Wallac (US) as exclusive distributor of its Quantase PKU neonatal screening assay. The test received US FDA 510(k) approval at the end of last year (see Clinica No 632, p 19).
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.